Cameron Santoro

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.

Here are the top 5 biosimilar articles for the week of March 24, 2025.

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.

Here are the top 5 biosimilar articles for the week of March 17, 2025.

Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following up to 4 switches between both drugs.

Here are the top 5 biosimilar articles for the week of March 10, 2025.

Here are the top 5 biosimilar articles for the week of March 3, 2025.

Here are the top 5 biosimilar articles for the week of February 24, 2025.

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin.

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.

Here are the top 5 biosimilar articles for the week of February 17, 2025.

Researchers treated postmenopausal women with osteoporosis with teriparatide biosimilar RGB-10, which improved their bone health measures and reduced fracture risk comparably to reference teriparatide.

Here are the top 5 biosimilar articles for the week of February 10, 2025.

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Here are the top 5 biosimilar articles for the week of February 3, 2025.

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD).

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.

Here are the top 5 biosimilar articles for the week of January 27, 2025.

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese regulatory agency approved a Stelara biosimilar.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52.

Here are the top 5 biosimilar articles for the week of January 20, 2025.

Here are the top 5 biosimilar articles for the week of January 13, 2025.

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.

Here are the top 5 biosimilar articles for the week of January 6, 2025.

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry.

No significant difference in the risk of serious infections between etanercept and infliximab biosimilars and their original brand-name medications was identified.

Here are the top 5 biosimilar articles for the week of December 30, 2024.

Here are the top 5 biosimilar articles for the week of December 16, 2024.

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing market share and reducing costs despite initial barriers.